Stock Traders Buy High Volume of Call Options on Arcadia Biosciences (NASDAQ:RKDA)

view original post

Arcadia Biosciences, Inc. (NASDAQ:RKDA) saw some unusual options trading on Tuesday. Stock investors bought 5,255 call options on the company. This represents an increase of 1,876% compared to the typical volume of 266 call options.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Arcadia Biosciences by 107.8% in the second quarter. Vanguard Group Inc. now owns 791,412 shares of the basic materials company’s stock worth $2,350,000 after purchasing an additional 410,506 shares during the period. Geode Capital Management LLC lifted its position in Arcadia Biosciences by 82.9% in the second quarter. Geode Capital Management LLC now owns 164,641 shares of the basic materials company’s stock worth $488,000 after purchasing an additional 74,646 shares during the period. MYDA Advisors LLC lifted its position in Arcadia Biosciences by 33.1% in the third quarter. MYDA Advisors LLC now owns 60,000 shares of the basic materials company’s stock worth $124,000 after purchasing an additional 14,921 shares during the period. Dimensional Fund Advisors LP lifted its position in Arcadia Biosciences by 310.3% in the second quarter. Dimensional Fund Advisors LP now owns 50,501 shares of the basic materials company’s stock worth $150,000 after purchasing an additional 38,194 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Arcadia Biosciences by 21.5% in the second quarter. Wells Fargo & Company MN now owns 45,124 shares of the basic materials company’s stock worth $134,000 after purchasing an additional 8,000 shares during the period. Institutional investors and hedge funds own 11.24% of the company’s stock.

Shares of NASDAQ RKDA opened at $1.39 on Wednesday. The stock has a 50 day simple moving average of $1.45 and a 200-day simple moving average of $2.04. The company has a market cap of $30.84 million, a PE ratio of 2.07 and a beta of -0.60. Arcadia Biosciences has a 12-month low of $0.97 and a 12-month high of $6.40.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings data on Monday, November 15th. The basic materials company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.13. The business had revenue of $2.38 million during the quarter, compared to the consensus estimate of $2.73 million. Arcadia Biosciences had a negative return on equity of 42.70% and a net margin of 39.19%. During the same period in the previous year, the firm posted ($0.54) earnings per share. As a group, equities research analysts forecast that Arcadia Biosciences will post -0.96 earnings per share for the current year.

Separately, HC Wainwright decreased their target price on Arcadia Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers.

Recommended Story: Catch-Up Contributions

Want More Great Investing Ideas?